Cutaneous immune-related adverse events from immune checkpoint inhibitor therapy: Moving beyond "maculopapular rash".

Allais, Blair S; Fay, Christopher J; Kim, Daniel Y; Semenov, Yevgeniy R; LeBoeuf, Nicole R

Allais, Blair S; Fay, Christopher J; Kim, Daniel Y; Semenov, Yevgeniy R; LeBoeuf, Nicole R.

Afiliação

Allais BS; Inova Schar Cancer Institute, Melanoma and Skin Cancer Center, Fairfax, Virginia, USA.
Fay CJ; The Center for Cutaneous Oncology, Department of Dermatology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts, USA.
Kim DY; Harvard-MIT Health Sciences and Technology Program, Harvard Medical School, Boston, Massachusetts, USA.
Semenov YR; Harvard Medical School, Boston, Massachusetts, USA.
LeBoeuf NR; Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts, USA.

Immunol Rev ; 318(1): 22-36, 2023 09.

Article em En | MEDLINE | ID: mdl-37583051

Assuntos

Exantema; Neoplasias; Humanos; Inibidores de Checkpoint Imunológico/efeitos adversos; Qualidade de Vida; Exantema/diagnóstico; Exantema/tratamento farmacológico; Exantema/patologia; Pele; Neoplasias/tratamento farmacológico; Neoplasias/patologia

Palavras-chave

cutaneous immune-related adverse events; immune checkpoint inhibitor; oncodermatology

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Exantema / Neoplasias Tipo de estudo: Diagnostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google